VRNA

Verona Pharma plc

23.02 USD
+0.44 (+1.95%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Verona Pharma plc stock is up 56.71% since 30 days ago. The next earnings date is Aug 1, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 62.5% of the previous 7 July’s closed higher than June. In the last 10 Unusual Options Trades, there were 1 PUT, 9 CALLs. 100% of analysts rate it a buy.

Options Flow Last 10
Date & Time Expiration Date Strike Price Trade Type Size Open Interest
16 Jul 19:58 16 Aug, 2024 22.50 PUT 228 17
17 Jul 13:45 20 Dec, 2024 30.00 CALL 170 3072
17 Jul 14:12 20 Dec, 2024 30.00 CALL 500 3072
17 Jul 14:14 20 Dec, 2024 30.00 CALL 1972 3072
17 Jul 16:54 20 Dec, 2024 25.00 CALL 88 150
18 Jul 14:04 19 Jul, 2024 20.00 CALL 318 5067
19 Jul 13:58 19 Jul, 2024 20.00 CALL 200 4720
19 Jul 13:58 19 Jul, 2024 20.00 CALL 200 4720
19 Jul 15:30 19 Jul, 2024 20.00 CALL 113 4720
19 Jul 17:55 19 Jul, 2024 20.00 CALL 194 4720

About Verona Pharma plc

Verona Pharma plc focuses on development and commercialization of therapies for respiratory diseases with unmet medical needs. Its product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes. Enfentrine is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis.

  • HC Wainwright & Co.
    Mon Jul 1, 07:00
    buy
    confirm
  • Truist Securities
    Fri Jun 28, 12:01
    buy
    confirm
  • Canaccord Genuity
    Thu Jun 27, 09:44
    buy
    confirm
  • HC Wainwright & Co.
    Thu Jun 27, 06:20
    buy
    confirm